RT Journal Article
SR Electronic
T1 Sensitivity assessment of SARS-CoV-2 PCR assays developed by WHO referral laboratories
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.03.20072207
DO 10.1101/2020.05.03.20072207
A1 Etievant, Sibyle
A1 Bal, Antonin
A1 Escuret, Vanessa
A1 Brengel–Pesce, Karen
A1 Bouscambert, Maude
A1 Cheynet, Valérie
A1 Generenaz, Laurence
A1 Oriol, Guy
A1 Destras, Gregory
A1 Billaud, Geneviève
A1 Josset, Laurence
A1 Frobert, Emilie
A1 Morfin, Florence
A1 Gaymard, Alexandre
YR 2020
UL http://medrxiv.org/content/early/2020/05/04/2020.05.03.20072207.abstract
AB The sensitivity of SARS-CoV-2 RT-PCR tests developed by Charité (Germany), HKU (Hong-Kong), China CDC (China), US CDC (United-States), and Institut Pasteur, Paris (France) was assessed on SARS-CoV-2 cell culture supernatants and clinical samples. Although all RT-PCR assays performed well for SARS-CoV-2 detection, RdRp Institut Pasteur (IP2, IP4), N China CDC, and N1 US CDC were found to be the most sensitive.Competing Interest StatementSE, VE, MB, GD, GB, LJ, EF, FM, AG have no conflicts of interest. AB has received a research grant from bioMérieux. KBP, VC, LG and GO are employees at bioMérieux.Funding StatementNo specific funding. Reagents were provided by Laboratoire Commun de Recherche Hospices Civils de Lyon – bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request